WO2023213983A3 - Construction d'expression - Google Patents

Construction d'expression Download PDF

Info

Publication number
WO2023213983A3
WO2023213983A3 PCT/EP2023/061877 EP2023061877W WO2023213983A3 WO 2023213983 A3 WO2023213983 A3 WO 2023213983A3 EP 2023061877 W EP2023061877 W EP 2023061877W WO 2023213983 A3 WO2023213983 A3 WO 2023213983A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
expression construct
knockdown
mirnas
different
Prior art date
Application number
PCT/EP2023/061877
Other languages
English (en)
Other versions
WO2023213983A2 (fr
Inventor
Marco ALESSANDRINI
Antonija ŠAKIC
Audrey ROUSSEL-GERVAIS
Sten ILMJÄRV
Original Assignee
Antion Biosciences Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antion Biosciences Sa filed Critical Antion Biosciences Sa
Publication of WO2023213983A2 publication Critical patent/WO2023213983A2/fr
Publication of WO2023213983A3 publication Critical patent/WO2023213983A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des constructions d'expression de miARN multiplexées pour l'expression d'au moins deux miARN différents et leurs utilisations pour inactiver l'expression génique cible. Dans certains aspects, les constructions d'expression de miARN multiplexées comprennent des miARN capables de cibler et d'inactiver l'expression d'au moins deux gènes différents ou plus.
PCT/EP2023/061877 2022-05-04 2023-05-04 Construction d'expression WO2023213983A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2206507.2A GB202206507D0 (en) 2022-05-04 2022-05-04 Expression construct
GB2206507.2 2022-05-04

Publications (2)

Publication Number Publication Date
WO2023213983A2 WO2023213983A2 (fr) 2023-11-09
WO2023213983A3 true WO2023213983A3 (fr) 2024-01-18

Family

ID=81943756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/061877 WO2023213983A2 (fr) 2022-05-04 2023-05-04 Construction d'expression

Country Status (2)

Country Link
GB (1) GB202206507D0 (fr)
WO (1) WO2023213983A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019033023A1 (fr) * 2017-08-11 2019-02-14 Baylor College Of Medicine Cellules nkt à cd1d restreint en tant que plateforme pour l'immunothérapie anticancéreuse en vente libre
WO2020221939A1 (fr) * 2019-05-02 2020-11-05 Celyad Cellules à arn inhibiteur multiplexé

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
EP1983056A1 (fr) 1992-07-07 2008-10-22 Japan Tobacco Inc. Procédé de transformation de monocotylédones
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
BR9306802A (pt) 1992-07-27 1998-12-08 Pioneer Hi Bred Int Processo independente de genótipos para produção de planta de soja transgénica e processo de regeneração de plantas de soja a partir de nodos cotiledonais
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ES2374290T3 (es) 1998-03-20 2012-02-15 Commonwealth Scientific And Industrial Research Organisation Genes sintéticos y constructos genéticos que comprenden los mismos.
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
JP2003525017A (ja) 1998-04-20 2003-08-26 リボザイム・ファーマシューティカルズ・インコーポレーテッド 遺伝子発現を調節しうる新規な化学組成を有する核酸分子
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
DE10224242A1 (de) 2002-05-29 2003-12-11 Max Delbrueck Centrum Frog Prince, ein Transposonvektor für den Gentransfer bei Wirbeltieren
JP2021519587A (ja) 2018-03-30 2021-08-12 ユニバーシティ オブ ジュネーブ マイクロｒｎａ発現構築物及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019033023A1 (fr) * 2017-08-11 2019-02-14 Baylor College Of Medicine Cellules nkt à cd1d restreint en tant que plateforme pour l'immunothérapie anticancéreuse en vente libre
WO2020221939A1 (fr) * 2019-05-02 2020-11-05 Celyad Cellules à arn inhibiteur multiplexé

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
A. ROUSSEL-GERVAIS1 A: "Immunotherapy: HIGH EFFICIENCY MULTIPLEX CELL ENGINEERING OF ALLOGENEIC, NEXT GENERATION CHIMERIC ANTIGEN RECEPTOR T-CELLS USING A SINGLE BIMODAL GENE CONSTRUCT", CYTOTHERAPY - ABSTRACTS OF THE 28 ANNUAL ISCT MEETING, 25 April 2022 (2022-04-25), pages 19 - 195, XP093059011, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/283374/1-s2.0-S1465324922X00042/1-s2.0-S1465324922003413/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEB8aCXVzLWVhc3QtMSJGMEQCIH802hdP6AhhkQ0PAZQMp684rXC2tg1mawV/HnjtDlWuAiAET7X3YRIOmYr0JYkEPj0/7gJubHMNylRBUONJq3yhTSq7BQiH//////////8BEAUaDDA1OTAwMzU0Njg2NSIMLVZ+r> [retrieved on 20230629] *
A. ROUSSEL-GERVAIS2: "MULTIPLEX GENE SILENCING AS A PROMISING TOOL FOR DEVELOPMENT OF NEXT GENERATION IMMUNE EFFECTOR CELL THERAPIES", CYTOTHERAPY - ABSTRACTS OF THE 27TH ANNUAL ISCT MEETING MAY 25-28, 2021, 1 May 2021 (2021-05-01), pages S85, XP093059032, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S1465324921003996> [retrieved on 20230629] *
FIGUEIREDO ET AL: "Creating immunologically invisible organs: Silencing mhc expression in an entire porcine lung during normothermic ex vivo perfusion", TRANSPLANT INTERNATIONAL., vol. 30, 1 October 2017 (2017-10-01), GB, pages 12 - 12, XP093095556, ISSN: 0934-0874, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Ftri.13063> DOI: 10.1111/tri.13063 *
FIGUEIREDO ET AL: "SILENCING SLA EXPRESSION IN THE LUNG ENDOTHELIUM SUPPORTS GRAFT SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION BY ABROGATING T-CELL MEDIATED IMMUNE RESPONSE", HLA, vol. 93, 10 April 2019 (2019-04-10), Hoboken, USA, pages 260 - 260, XP093095549, ISSN: 2059-2302, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/tan.13518> DOI: 10.1111/tan.13518 *
GILHAM D E ET AL: "Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells", JOURNAL OF CLINICAL ONCOLOGY (2020 ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM); 2020 ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, ASCO 2020 20200529 TO 20200602 CHICAGO, IL, LIPPINCOTT WILLIAMS & WILKINS, USA, vol. 38, no. 15, 1 January 2020 (2020-01-01), XP009541172, ISSN: 1527-7755 *
GILHAM D E: "Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells. | Journal of Clinical Oncology", JOURNAL OF CLINICAL ONCOLOGY, 2 June 2020 (2020-06-02), XP093059025, Retrieved from the Internet <URL:https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.3103> [retrieved on 20230629] *
GILHAM DAVID E ET AL: "Abstract 3103: Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T-cells", 2020 ASCO ANNUAL MEETING I, 25 May 2020 (2020-05-25), XP093016850, Retrieved from the Internet <URL:https://celyad.com/wp-content/uploads/2020/06/2020_ASCO_Annual_Meeting-shRNA-final.pdf> [retrieved on 20230124] *
HU XIAOMENG ET AL: "Engineered Hypoimmune Allogeneic CAR T Cells Exhibit Innate and Adaptive Immune Evasion Even after Sensitization in Humanized Mice and Retain Potent Anti-Tumor Activity", BLOOD, vol. 138, no. Supplement 1, 23 November 2021 (2021-11-23), US, pages 1690 - 1690, XP055918301, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/138/Supplement%201/1690/480197/Engineered-Hypoimmune-Allogeneic-CAR-T-Cells> *
KAGOYA YUKI ET AL: "Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy", CANCER IMMUNOLOGY RESEARCH, vol. 8, no. 7, 1 July 2020 (2020-07-01), US, pages 926 - 936, XP055914136, ISSN: 2326-6066, Retrieved from the Internet <URL:https://watermark.silverchair.com/926.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAuQwggLgBgkqhkiG9w0BBwagggLRMIICzQIBADCCAsYGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM3gGpTjOf5WrQ0LSxAgEQgIICl4nUgREH5HMR_YEzNFkckDkfbaZsoXS77_qJkqXIYX2aoTlEiGKFIJhqNEcW3xI2iwXeRK6KzXHAnsMCDKm9ZkHJyBlCXcfv> DOI: 10.1158/2326-6066.CIR-18-0508 *
MATTHES T ET AL: "Development of anti-CD19 CAR T-cells with immune checkpoint silencing", ASGCT ANNUAL MEETING 2021, 1 January 2021 (2021-01-01), XP093042144, Retrieved from the Internet <URL:https://antionbio.com/public/posters/No1473__Matthes_T__ASGCT_Poster.pdf> [retrieved on 20230425] *
ROUSSEL-GERVAIS A ET AL: "A novel bimodal construct for multiplex cell engineering and the development of allogeneic chimeric antigen receptor T-cells", ASGCT ANNUAL MEETING 2021, 1 January 2021 (2021-01-01), XP093042147, Retrieved from the Internet <URL:https://antionbio.com/public/posters/No1477__Roussel-Gervais_A__ASGCT_Poster.pdf> [retrieved on 20230425] *
STEKLOV MIKHAIL ET AL: "146?Evolving Mutliplexed shRNA to generate tailored CAR T cell therapy", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. Suppl 2, 1 November 2021 (2021-11-01), pages A154 - A154, XP093059020, Retrieved from the Internet <URL:https://jitc.bmj.com/content/jitc/9/Suppl_2/A154.full.pdf> DOI: 10.1136/jitc-2021-SITC2021.146 *
VALDIVIA EMILIO ET AL: "Genetic Modification of Limbal Stem Cells to Decrease Allogeneic Immune Responses", FRONTIERS IN IMMUNOLOGY, vol. 12, 9 December 2021 (2021-12-09), XP093058344, DOI: 10.3389/fimmu.2021.747357 *

Also Published As

Publication number Publication date
GB202206507D0 (en) 2022-06-15
WO2023213983A2 (fr) 2023-11-09

Similar Documents

Publication Publication Date Title
AU2018253578A1 (en) RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3693464A3 (fr) Compositions et procédés d&#39;inhibition de l&#39;expression des gènes de l&#39;apolipoprotéine c-iii (apoc3)
WO2018191278A3 (fr) Compositions ciblées
PE20190844A1 (es) Modulacion de transcripcion con arn de direccion a adn generico
WO2008156702A3 (fr) Extinction de gènes médiée par des bactéries
WO2011072082A3 (fr) Modulation de l&#39;expression de hsp47
ZA202006505B (en) Micro rna expression constructs and uses thereof
ZA202101298B (en) Multi-targeting nucleic acid constructs composed of multiple oligonucleotides that modulate gene expression through complimentary interactions with targets
MX2022000183A (es) Lipidos cationicos y usos de estos.
SG10201907746TA (en) Methods of treating cancer harboring hemizygous loss of tp53
MX2022006846A (es) Conjugados y metodos para tratar la fibrosis hepatica.
MX2022006748A (es) Composiciones de acidos nucleicos.
WO2010107955A3 (fr) Inhibition médiée par arn interférence de l&#39;expression génique de btb et de l&#39;homologie cnc 1, facteur de transcription 1 de fermeture éclair de leucine basique (bach 1), utilisant une liste de séquences d&#39;acide nucléique interférant court (ansi)
EP4335502A3 (fr) Système promoteur u6 modifié pour expression spécifique de tissu
CL2021002842A1 (es) Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas
WO2022072950A8 (fr) Nucléoside contenant des arnsi pour traiter des maladies virales
WO2005086896A3 (fr) Vecteurs de delivrance d&#39;un petit arn interferant, micro-arn et arn anti-sens
WO2020104649A3 (fr) Nouvelles compositions d&#39;arn et méthodes d&#39;inhibition d&#39;angptl8
MX2022012561A (es) Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
WO2023213983A3 (fr) Construction d&#39;expression
WO2023081500A3 (fr) Conjugués oligonucleotides/arni
MX2023014976A (es) Composiciones y metodos para silenciar la expresion de miocilina (myoc).
MX2022002689A (es) Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
AU2015262889A8 (en) Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) autosomal dominant osteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation
WO2022235975A3 (fr) Constructions d&#39;arnsi pour inhiber l&#39;expression génique dans des cellules cancéreuses ciblées